Navigation Links
NHP Announces Second Quarter Earnings Release Date and Conference Call/Webcast
Date:7/7/2008

NEWPORT BEACH, Calif., July 7 /PRNewswire-FirstCall/ -- Nationwide Health Properties, Inc. (NYSE: NHP) announced today that the Company will release its second quarter earnings on Wednesday, August 6, 2008 after the close of trading on the New York Stock Exchange. The Company will host a conference call on Thursday, August 7, 2008 at 8:30 a.m. Pacific time (11:30 a.m. Eastern time) in order to present the Company's financial performance and operating results for the second quarter ended June 30, 2008.

The conference call will be accessible by dialing 877-356-5705 and referencing conference ID number 55064086 or by logging on to our website at http://www.nhp-reit.com. The international dial-in number is 706-643-7409. The earnings release and any additional financial information that may be discussed on the conference call will also be available on our website. A digitized replay of the conference call will be available from 10:30 a.m. Pacific time (1:30 p.m. Eastern time) that day until 9:00 p.m. Pacific time (Midnight Eastern time) Friday, September 5, 2008. Callers can access the replay by dialing (800) 642-1687 or (706) 645-9291 and entering conference ID number 55064086. Webcast replays will also be available on our website for at least 12 months following the conference call.

Nationwide Health Properties, Inc. is a real estate investment trust that invests in health care facilities. The Company has investments in 562 facilities in 43 states. For more information on Nationwide Health Properties, Inc. visit our website at http://www.nhp-reit.com.

Certain information contained in this release includes forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are not statements of historical facts, including statements regarding the proposed transaction between NHP and PMB and the benefits of the proposed transaction. These statements may be identified, without limitation, by the use of forward-looking terminology such as "may," "will," "anticipates," "expects," "believes," "intends," "should" or comparable terms or the negative thereof. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those described in the statements. Risks and uncertainties associated with the PMB transaction include (without limitation) the following: delay or failure to obtain third party consents; the exclusion of certain properties (which may include properties described herein) from the transaction; uncertainty as to whether the transaction will be completed; the failure to achieve the perceived advantages from the transaction; larger than expected or unexpected costs associated with the transaction; unexpected liabilities resulting from the transaction; potential litigation associated with the transaction; and the retention of key personnel after the transaction. Other risks and uncertainties associated with our business, many of which will apply to the assets acquired in the PMB transaction, include (without limitation) the following: deterioration in the operating results or financial condition, including bankruptcies, of our tenants; non-payment or late payment of rent by our tenants; our reliance on two operators for a significant percentage of our revenues; occupancy levels at certain facilities; our level of indebtedness; changes in the ratings of our debt securities; access to the capital markets and the cost of capital; government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs; the general distress of the healthcare industry; increasing competition in our business sector; the effect of economic and market conditions and changes in interest rates; the amount and yield of any additional investments; our ability to meet acquisition goals; the ability of our operators to repay deferred rent or loans in future periods; the ability of our operators to obtain and maintain adequate liability and other insurance; our ability to attract new operators for certain facilities; our ability to sell certain facilities for their book value; our ability to retain key personnel; potential liability under environmental laws; the possibility that we could be required to repurchase some of our medium-term notes; the rights and influence of holders of our outstanding preferred stock; changes in or inadvertent violations of tax laws and regulations and other factors that can affect real estate investment trusts and our status as a real estate investment trust; and other factors discussed from time to time in our news releases, public statements and/or filings with the Securities and Exchange Commission, especially the "Risk Factors" sections of our Annual and Quarterly Reports on Forms 10-K and 10-Q. Forward-looking information is provided by NHP pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of these factors. We disclaim any intent or obligation to update these forward-looking statements.

CONTACT: Ron M. Hubbard

Vice President - Capital Markets & Investor Relations

(949) 717-0133


'/>"/>
SOURCE Nationwide Health Properties, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ventas Announces 2008 Second Quarter Earnings Release Date and Conference Call
2. QuikByte Software, Inc. Announces Changes to Board of Directors and Executive Ranks
3. March of Dimes Announces Nursing Scholarship Recipients
4. Zix Corporation Announces Webcast Showcasing Email Encryption Competitive Replacement
5. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
6. Mindray Announces 20-F Filing
7. Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index
8. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
9. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
10. Hooper Holmes Announces Sale of Claims Evaluation Division
11. Transition Therapeutics Announces Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: